NCT04105153View on ClinicalTrials.gov

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

CompletedOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions
EGFR Positive Non-small Cell Lung Cancer
Trial Locations (1)

69126

Thoraxklinik-Heidelberg gGmbH - Universitätsklinikum Heidelberg, Heidelberg

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Thoraxklinik-Heidelberg gGmbH

OTHER